JUBILANT PHARMOVA LTD.

NSE : JUBLPHARMABSE : 530019ISIN CODE : INE700A01033Industry : Pharmaceuticals & DrugsHouse : Jubilant Bhartia
BSE933.80-40.7 (-4.18 %)
PREV CLOSE ( ) 974.50
OPEN PRICE ( ) 965.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 13828
TODAY'S LOW / HIGH ( )928.20 975.00
52 WK LOW / HIGH ( )823.7 1250
NSE937.65-36.2 (-3.72 %)
PREV CLOSE( ) 973.85
OPEN PRICE ( ) 973.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 937.65 (493)
VOLUME 387845
TODAY'S LOW / HIGH( ) 929.60 976.40
52 WK LOW / HIGH ( )802 1248
( in Million)
Select year
ParticularsMar2025Mar2024Mar2023Mar2022Mar2021
Profit Before Tax9806.001705.00278.006304.4712120.10
Adjustment2181.007554.007829.005794.747164.75
Changes In working Capital1118.002531.00543.00-1782.872499.00
Cash Flow after changes in Working Capital13105.0011790.008650.0010316.3421783.85
Cash Flow from Operating Activities10721.009713.006607.008375.4317842.65
Cash Flow from Investing Activities4877.00-6079.00-5444.00-3803.70-7390.14
Cash Flow from Financing Activities-14527.00-4325.00-1567.00-325.99-17093.86
Net Cash Inflow / Outflow1071.00-691.00-404.004245.74-6641.35
Opening Cash & Cash Equivalents9564.0010139.009838.005019.5712308.14
Cash & Cash Equivalent on Amalgamation / Take over / MergerNANANANA-769.81
Cash & Cash Equivalent of Subsidiaries under liquidationsNANANANANA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNANANANANA
Effect of Foreign Exchange Fluctuations248.00116.00705.00572.88122.59
Closing Cash & Cash Equivalent10883.009564.0010139.009838.195019.57

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.